These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23211261)

  • 41. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.
    Schuster H; Barter PJ; Stender S; Cheung RC; Bonnet J; Morrell JM; Watkins C; Kallend D; Raza A;
    Am Heart J; 2004 Apr; 147(4):705-13. PubMed ID: 15077101
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Implications of American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Guidelines on Statin Underutilization for Prevention of Cardiovascular Disease in Diabetes Mellitus Among Several US Networks of Community Health Centers.
    Akhabue E; Rittner SS; Carroll JE; Crawford PM; Dant L; Laws R; Leo MC; Puro J; Persell SD
    J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28673901
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Achievement of therapeutic target in subjects on statin treatment in clinical practice. Results of the STAR (Statins Target Assessment in Real practice) study].
    Degli Esposti L; Sangiorgi D; Arca M; Vigna GB; Budal S; Degli Esposti E
    Monaldi Arch Chest Dis; 2011 Dec; 76(4):160-7. PubMed ID: 22567731
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prescription of suboptimal statin treatment regimens: a retrospective cohort study of trends and variation in English primary care.
    Curtis HJ; Walker AJ; MacKenna B; Croker R; Goldacre B
    Br J Gen Pract; 2020 Aug; 70(697):e525-e533. PubMed ID: 32601055
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of Cost-Effectiveness, Safety, and Efficacy of Rosuvastatin Versus Atorvastatin, Pravastatin, and Simvastatin in Dyslipidemic Diabetic Patients With or Without Metabolic Syndrome.
    Bener A; Dogan M; Barakat L; Al-Hamaq AO
    J Prim Care Community Health; 2014 Jul; 5(3):180-7. PubMed ID: 24522932
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Co-medication of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy.
    Devold HM; Molden E; Skurtveit S; Furu K
    Br J Clin Pharmacol; 2009 Feb; 67(2):234-41. PubMed ID: 19220274
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets.
    Lachaine J; Merikle E; Tarride JE; Montpetit M; Rinfret S
    Clin Ther; 2007 Mar; 29(3):519-28. PubMed ID: 17577472
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Statin prescribing in the elderly in the Netherlands: a pharmacy database time trend study.
    Geleedst-De Vooght M; Maitland-van der Zee AH; Schalekamp T; Mantel-Teeuwisse A; Jansen P
    Drugs Aging; 2010 Jul; 27(7):589-96. PubMed ID: 20583852
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Titration patterns with rosuvastatin as compared with other statins in clinical practice: a retrospective observational cohort study using an electronic medical record database.
    Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Davidson MH
    Clin Ther; 2007 Nov; 29(11):2385-94. PubMed ID: 18158079
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era.
    Lazar LD; Pletcher MJ; Coxson PG; Bibbins-Domingo K; Goldman L
    Circulation; 2011 Jul; 124(2):146-53. PubMed ID: 21709063
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Do doctors in dispensing practices with a financial conflict of interest prescribe more expensive drugs? A cross-sectional analysis of English primary care prescribing data.
    Goldacre B; Reynolds C; Powell-Smith A; Walker AJ; Yates TA; Croker R; Smeeth L
    BMJ Open; 2019 Feb; 9(2):e026886. PubMed ID: 30813120
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Age, sex and practice variations in the use of statins in general practice in England and Wales.
    Majeed A; Moser K; Maxwell R
    J Public Health Med; 2000 Sep; 22(3):275-9. PubMed ID: 11077897
    [TBL] [Abstract][Full Text] [Related]  

  • 54. LDL-C goal attainment in patients who remain on atorvastatin or switch to equivalent or non-equivalent doses of simvastatin: a retrospective matched cohort study in clinical practice.
    Rublee DA; Burke JP
    Postgrad Med; 2010 Mar; 122(2):16-24. PubMed ID: 20203452
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A cost-effectiveness model of alternative statins to achieve target LDL-cholesterol levels.
    Maclaine GD; Patel H
    Int J Clin Pract; 2001 May; 55(4):243-9. PubMed ID: 11406909
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Statin Selection in Qatar Based on Multi-indication Pharmacotherapeutic Multi-criteria Scoring Model, and Clinician Preference.
    Al-Badriyeh D; Fahey M; Alabbadi I; Al-Khal A; Zaidan M
    Clin Ther; 2015 Dec; 37(12):2798-810. PubMed ID: 26299479
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Statin Prescribing Patterns: An Analysis of Data From Patients With Diabetes in the National Hospital Ambulatory Medical Care Survey Outpatient Department and National Ambulatory Medical Care Survey Databases, 2005-2010.
    Pauff BR; Jiroutek MR; Holland MA; Sutton BS
    Clin Ther; 2015 Jun; 37(6):1329-39. PubMed ID: 25869626
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multilevel analysis of the influence of patients' and general practitioners' characteristics on patented versus multiple-sourced statin prescribing in France.
    Pichetti S; Sermet C; Godman B; Campbell SM; Gustafsson LL
    Appl Health Econ Health Policy; 2013 Jun; 11(3):205-18. PubMed ID: 23609765
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Pharmaco-economic optimization of cholesterol-lowering treatment with statins].
    Ruiz García A; Gordillo López FJ; Arranz Martínez E; Hermosa Hernán JC
    Med Clin (Barc); 2011 Jun; 137(3):119-25. PubMed ID: 21074814
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Achievement of LDL-cholesterol goal with statins after an st segment elevation myocardial infarction.
    Tungsubutra W; Phongtuntakul B
    J Med Assoc Thai; 2015 Feb; 98(2):129-36. PubMed ID: 25842792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.